carolina complete health

Pharmacy Prior Approval Request for Viekira Pak

Member Information

1. Member Last Name: _____ 2. First Name: _____
3. Member ID #: _____4. Member Date of Birth: _____ 5. Member Gender: _____

Prescriber Information

6. Prescribing Provider NPI #: _____
7. Requester Contact Information - Name: _____ Phone #: _____ Ext. _____

Drug Information

8. Drug Name: _____ 9. Strength: _____ 10. Quantity Per 30 Days: 112
11. Length of Therapy (in days): ☐ 12 Weeks ☐24 Weeks

Clinical Information

Total Length of Therapy (Check ONE):

☐ **12 weeks** = Genotype 1a, without cirrhosis, or genotype 1b, with cirrhosis

☐ **24 weeks =** Genotype 1a, with compensated cirrhosis

1. Is the Member 18 years of age or older with a diagnosis of chronic hepatitis C (CHC) infection with confirmed genotype 1 b without cirrhosis or with compensated cirrhosis or confirmed genotype 1a without cirrhosis or with compensated cirrhosis in combination with ribavirin? ☐ **Yes** ☐ **No**
   Genotype is: _____
2. For all treatment courses except genotype 1b (without cirrhosis), will treatment include the use of ribavirin?
   ☐ **Yes** ☐ **No**
3. Have medical records documenting the diagnosis of chronic hepatitis C with genotype and subtype been submitted?
   ☐ **Yes** ☐ **No** ****Lab test results MUST be attached to the PA to be approved.****
4. Does the Member have a documented quantitative HCV RNA at baseline that was tested within the past 6 months (medical documentation required)? ☐ **Yes** ☐ **No HCV RNA (IU/ml):** _____ and/or **log10 value:** _____
5. As the provider, are you reasonably certain that treatment will improve the Member's overall health status?
   ☐ **Yes** ☐**No**
6. Has the provider assessed for laboratory and clinical evidence of hepatic decompensation? ☐ **Yes** ☐ **No**
7. Does the Member have cirrhosis? ☐ **Yes** ☐ **No** If answer is yes, please answer the following:
   7a. Is the Member being monitored for clinical signs and symptoms of hepatic decompensation (such as ascites, hepatic encephalopathy, variceal hemorrhage)? ☐ **Yes** ☐ **No**
   7b. Has the Member received hepatic laboratory testing including direct bilirubin levels at baseline and during the first four weeks of starting treatment and as clinically indicated? ☐ **Yes** ☐ **No**

Continued on next page

8. Is Viekira Pak being used in combination with other protease inhibitors used to treat CHC (i.e. boceprevir, simeprevir, or telaprevir) or in combination with another nucleotide NS5B polymerase inhibitor such as Sovaldi® (sofosbuvir)? ☐ **Yes** ☐ **No**

9. Is the Member using Viekira Pak in combination with another NS5A inhibitor? ☐ **Yes** ☐ **No**

10. Is the Member requesting the regimen for re-treatment and either failed to achieve a SVR (defined as a lower limit HCV RNA of 25 IU/mL) or relapsed after achieving a SVR during a prior successfully completed treatment regimen consisting of Sofosbuvir? ☐ **Yes** ☐ **No**

11. Is the Member requesting the regimen for re-treatment and either failed to achieve a SVR (defined as a lower limit HCV RNA of 25 IU/mL) or relapsed after achieving a SVR during a prior successfully completed treatment regimen consisting of Ledipasvir? ☐ **Yes** ☐ **No**

12. Does the Member have decompensated liver disease as defined by Child-Pugh classification score of Child Class B or C (VIEKIRA PAK™ is contraindicated in beneficiaries with moderate to severe hepatic impairment (Child-Pugh B and C)? ☐ **Yes** ☐ **No**

13. Has the Member attempted a previous course of therapy with Viekira Pak? ☐ **Yes** ☐ **No**

14. Does the Member have any FDA labeled contraindications to Viekira Pak? ☐ **Yes** ☐ **No**

Signature of Prescriber: _____ Date: _____

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.